This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Mirati Therapeutics Performance dei guadagni passati
Il passato criteri di controllo 0/6
Mirati Therapeutics's earnings have been declining at an average annual rate of -35.9%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 34.7% per year.
Informazioni chiave
-35.9%
Tasso di crescita degli utili
-26.2%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | 34.7% |
| Rendimento del capitale proprio | -76.7% |
| Margine netto | -1,900.7% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2023 |
Aggiornamenti sulle prestazioni recenti
Recent updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
May 17We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates
Dec 09We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?
Sep 11Mirati: A Potential Blockbuster Stock, Will Need Patience
Sep 08Mirati jumps 11% as Amgen meets key goal for rival cancer drug
Aug 31Mirati gains as Amgen posts new combination data for rival cancer drug
Aug 08Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
Aug 08Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
Jun 21Ripartizione dei ricavi e delle spese
Come Mirati Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 23 | 38 | -726 | 292 | 0 |
| 30 Jun 23 | 27 | -738 | 281 | 0 |
| 31 Mar 23 | 19 | -737 | 259 | 0 |
| 31 Dec 22 | 12 | -741 | 240 | 0 |
| 30 Sep 22 | 12 | -738 | 213 | 0 |
| 30 Jun 22 | 78 | -645 | 187 | 0 |
| 31 Mar 22 | 73 | -634 | 162 | 0 |
| 31 Dec 21 | 72 | -582 | 137 | 0 |
| 30 Sep 21 | 74 | -483 | 118 | 0 |
| 30 Jun 21 | 13 | -491 | 104 | 0 |
| 31 Mar 21 | 13 | -407 | 94 | 0 |
| 31 Dec 20 | 13 | -358 | 83 | 0 |
| 30 Sep 20 | 12 | -329 | 70 | 0 |
| 30 Jun 20 | 2 | -296 | 61 | 0 |
| 31 Mar 20 | 2 | -259 | 51 | 0 |
| 31 Dec 19 | 3 | -213 | 43 | 0 |
| 30 Sep 19 | 6 | -169 | 37 | 0 |
| 30 Jun 19 | 5 | -142 | 31 | 0 |
| 31 Mar 19 | 5 | -125 | 26 | 0 |
| 31 Dec 18 | 13 | -98 | 22 | 0 |
| 30 Sep 18 | 9 | -88 | 18 | 0 |
| 30 Jun 18 | 9 | -77 | 16 | 0 |
| 31 Mar 18 | 9 | -67 | 15 | 0 |
| 31 Dec 17 | 0 | -70 | 13 | 0 |
| 30 Sep 17 | 0 | -72 | 14 | 13 |
| 30 Jun 17 | 0 | -75 | 15 | 30 |
| 31 Mar 17 | 0 | -79 | 15 | 48 |
| 31 Dec 16 | 0 | -83 | 15 | 0 |
| 30 Sep 16 | 0 | -82 | 15 | 67 |
| 30 Jun 16 | 0 | -81 | 16 | 66 |
| 31 Mar 16 | 0 | -75 | 16 | 59 |
| 31 Dec 15 | 0 | -65 | 16 | 49 |
| 30 Sep 15 | 0 | -57 | 16 | 41 |
| 30 Jun 15 | 0 | -46 | 15 | 33 |
| 31 Mar 15 | 0 | -42 | 14 | 29 |
| 31 Dec 14 | 0 | -44 | 13 | 26 |
| 30 Sep 14 | 0 | -45 | 12 | 23 |
| 30 Jun 14 | 0 | -65 | 12 | 22 |
| 31 Mar 14 | 0 | -62 | 11 | 19 |
| 31 Dec 13 | 0 | -53 | 11 | 20 |
| 30 Sep 13 | 0 | -48 | 10 | 20 |
| 30 Jun 13 | 0 | -24 | 8 | 19 |
Guadagni di qualità: MRTX is currently unprofitable.
Margine di profitto in crescita: MRTX is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: MRTX is unprofitable, and losses have increased over the past 5 years at a rate of 35.9% per year.
Accelerare la crescita: Unable to compare MRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: MRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Rendimento del capitale proprio
ROE elevato: MRTX has a negative Return on Equity (-76.69%), as it is currently unprofitable.